Bradicardia inestable ACLS

Bradycardia and Hemodynamic Instability Management

Definition of Unstable Bradycardia

• Unstable bradycardia is defined as a heart rate below 60 beats per minute, accompanied by hemodynamic compromise.

• Symptoms include hypotension (systolic blood pressure < 90 mmHg), altered mental status (confusion, disorientation, acute lethargy), signs of shock or heart failure (cold, pale, clammy skin; slow capillary refill), and ischemic chest pain due to low perfusion.

Initial Approach to Patient Management

• The initial management begins with a rapid primary assessment and stabilization measures. Oxygen should be administered if necessary.

• Reversible causes must be identified and ruled out using the "5 H's" (hypovolemia, hypoxia, hydrogen ions, hypo/hyperkalemia, hypothermia) and "5 T's" (tension pneumothorax, cardiac tamponade, toxic ingestion, pulmonary or coronary thrombosis).

Therapeutic Algorithm for Bradycardia

• The main goal is not just achieving an acceptable heart rate but ensuring it is sufficient to restore organ perfusion and alleviate symptoms gradually.

• Therapeutic objectives include resolving hypotension, improving mental status, alleviating ischemic chest pain, and increasing urinary output as other symptoms improve.

First-Line Medication: Atropine

• After initial management with oxygen and IV access in place for bradycardia treatment starts with atropine at a dose of 1 mg IV every 3 to 5 minutes up to a maximum of 3 mg.

• Atropine is effective for vagal stimulation-induced bradycardia or AV block but may fail in distal blocks or ischemia. Caution is advised in patients with acute myocardial infarction due to increased oxygen demand.

Second-Line Medications: Dopamine and Epinephrine

• If atropine fails, second-line agents like dopamine (infusion of 5–20 mcg/minute) or epinephrine (2–10 mcg/kg/minute) can be used. These should be titrated until desired effects are achieved.

• If these medications do not yield results either, transcutaneous pacing may be employed as an urgent but temporary non-invasive measure to increase heart rate.

Transcutaneous Pacing Procedure

• This involves placing pacing electrodes on the chest in an anterior-posterior position starting at a frequency of 60–80 beats per minute. Sedation may be required due to discomfort from this method.

Definitive Therapy: Transvenous Pacemaker

• While atropine and catecholamines provide urgent relief for bradycardia symptoms, definitive therapy involves consulting an expert for transvenous pacemaker placement—either temporary or permanent—to regulate slow or irregular heart rhythms effectively.

Summary Steps in Management Algorithm

• Step one: Identify bradycardia signs such as hypotension and altered mental state.

• Step two: Conduct initial evaluation including oxygen needs and airway management.

Management of Bradycardia

Initial Steps in Bradycardia Management

• The management begins with identifying reversible causes using the "5 H's and 5 T's" framework.

• If bradycardia is confirmed and the patient shows signs of instability, intubation should be performed, and intravenous access established.

Pharmacological Interventions

• Atropine is administered at a dose of 1 mg, with a maximum limit of 3 mg if initial doses are ineffective.

• If atropine is unavailable or ineffective, second-line medications include dopamine infusion (5 to 20 mcg/kg/min) or epinephrine infusion (2 to 10 mcg/min), both titrated for patient response.

Additional Measures

• Transcutaneous pacing is also considered as a secondary measure if pharmacological interventions do not resolve the bradycardia.